The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
Oncologist. 2020 Aug;25(8):680-688. doi: 10.1634/theoncologist.2019-0851. Epub 2020 May 13.
DNA damage response (DDR) genomic alterations may play an important role in clinical outcomes of patients with urothelial cancer (UC). However, data on the prognostic role of DDR gene alterations in patients with advanced UC remain unclear.
We retrospectively collected data of three independent patient cohorts with relapsed or advanced UC including 81 and 91 patients from four institutions who underwent FoundationOne genomic sequencing as well as 129 patients selected from The Cancer Genome Atlas bladder cohort. Fisher's exact test was used to determine differences of mutation frequency among the three cohorts. Logistic regression analysis was performed to calculate odds ratio (OR) and 95% confidence interval (CI). Overall survival (OS) was measured from time of initial diagnosis and Cox proportional hazard regression analysis was performed to calculate the hazard ratio (HR) and 95% CI.
DDR genomic alterations were present in 76.5% (62/81), 40.7% (37/91), and 51.2% (66/129) of the three cohorts. ATM alterations consistently correlated with significantly shorter OS, whereas other DDR alterations (excluding ATM) were associated with better prognosis. In 152 patients treated with platinum pooled from the three cohorts, the prognostic value of alterations in ATM as compared with other predefined DDR genes was substantially different (ATM: adjusted HR [HR], 2.03; 95% CI, 1.03-4; p = .04; other DDR: adjusted HR, 0.49; 95% CI, 0.31-0.8; p = .003).
Genomic alterations in ATM and other DDR genes may have opposite prognostic value in relapsed and/or advanced UC. ATM may have a complex role in UC progression.
Somatic mutations of DNA damage response (DDR) genes are frequently found in urothelial cancer and appear to play an important role in tumorigenesis, progression, treatment response, and outcomes. In a set of DDR genes, ATM alterations were associated with worse survival, while other alterations were associated with better survival in advanced urothelial cancer. The results of this study suggest a complex role of ATM in tumor progression and call for further studies to determine the underlying mechanisms and biomarker clinical utility.
DNA 损伤反应 (DDR) 基因组改变可能在尿路上皮癌 (UC) 患者的临床结局中发挥重要作用。然而,关于 DDR 基因改变在晚期 UC 患者中的预后作用的数据尚不清楚。
我们回顾性收集了三个独立的复发性或晚期 UC 患者队列的数据,其中包括来自四个机构的 81 名和 91 名接受 FoundationOne 基因组测序的患者,以及从癌症基因组图谱膀胱队列中选择的 129 名患者。Fisher 确切检验用于确定三个队列之间突变频率的差异。进行逻辑回归分析计算优势比 (OR) 和 95%置信区间 (CI)。总生存期 (OS) 从初始诊断时间开始测量,并进行 Cox 比例风险回归分析计算风险比 (HR) 和 95%CI。
三个队列中 DDR 基因组改变分别为 76.5%(62/81)、40.7%(37/91)和 51.2%(66/129)。ATM 改变与明显较短的 OS 一致相关,而其他 DDR 改变(不包括 ATM)与更好的预后相关。在三个队列中合并的 152 名接受铂类治疗的患者中,与其他预定义的 DDR 基因相比,ATM 改变的预后价值差异很大(ATM:调整 HR [HR],2.03;95%CI,1.03-4;p =.04;其他 DDR:调整 HR,0.49;95%CI,0.31-0.8;p =.003)。
复发和/或晚期 UC 中 ATM 和其他 DDR 基因的基因组改变可能具有相反的预后价值。ATM 在 UC 进展中可能具有复杂的作用。
DNA 损伤反应 (DDR) 基因的体细胞突变在尿路上皮癌中经常发现,并且似乎在肿瘤发生、进展、治疗反应和结果中发挥重要作用。在一组 DDR 基因中,ATM 改变与生存较差相关,而其他改变与晚期尿路上皮癌的生存较好相关。这项研究的结果表明 ATM 在肿瘤进展中的复杂作用,并呼吁进一步研究以确定潜在的机制和生物标志物的临床实用性。